COLL

Leadership Change at Avalo Therapeutics: Michael Heffernan has been appointed as the new Chairman of the Board of Directors for Avalo Therapeutics, succeeding Dr. Garry Neil, who remains as CEO and board member.

Focus on Immune Dysregulation Treatments: Avalo is advancing its pipeline of therapies for immune-mediated diseases, particularly highlighting its lead candidate AVTX-009, which is currently in Phase 2 trials for hidradenitis suppurativa.

Board Changes and New Appointments: Gino Santini has been appointed as Chairman of the Board of Collegium Pharmaceutical, while Michael Heffernan and Gwen A. Melincoff will retire from the Board. Dr. Carlos Paya is nominated for a Board position, and three new executives have been added to the leadership team.

Company Growth Strategy: Collegium Pharmaceutical aims to enhance its growth phase by focusing on its pain management portfolio and the recently acquired ADHD treatment, Jornay PM, while strategically deploying capital to create shareholder value.

Collegium Pharmaceutical Presentation: Collegium Pharmaceutical will present real-world data on its ADHD treatment, Jornay PM, at the NAPNAP conference in Chicago from March 10-13, 2025, focusing on medication persistence and adherence.

Jornay PM Overview: Jornay PM is a CNS stimulant indicated for individuals aged six and older with ADHD, associated with potential side effects and risks, including abuse.

Collegium Pharmaceutical Presentation: Collegium Pharmaceutical announced two poster presentations at the NAPNAP conference, showcasing real-world data on its ADHD treatment, Jornay PM, emphasizing its benefits for patients with attention deficit hyperactivity disorder.

About Jornay PM: Jornay PM is a CNS stimulant approved for treating ADHD in individuals aged six and older, but it carries risks of abuse, dependence, and serious side effects, necessitating careful monitoring by healthcare providers.

Collegium Pharmaceutical Overview: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a specialty pharmaceutical company focusing on abuse-deterrent opioid medications for chronic pain management and has recently expanded into neurology with the acquisition of Ironshore Therapeutics. The company reported strong financial performance in Q3 2024, achieving a record net revenue of $159.3 million and reaffirming its 2024 financial guidance.

Industry Insights: Emily Field from Barclays discussed the pharmaceutical industry's outlook, particularly regarding obesity medications and the impact of US tariffs, while Eli Lilly's Chief Scientific Officer highlighted opportunities in weight reduction treatments. Despite the potential of COLL as an investment, there is a belief that AI stocks may offer higher returns in a shorter timeframe.

Strong Financial Performance: Collegium Pharmaceutical reported fourth-quarter earnings of $1.75 per share and revenue of $181.9 million, both surpassing analyst expectations and reflecting a 22% year-over-year increase.

Growth in Product Portfolio: The company's growth was driven by significant increases in prescriptions for Jornay PM and Belbuca, with the latter achieving record net revenues, while Collegium reaffirmed its 2025 revenue guidance between $735 million and $750 million.

Financial Performance: Collegium Pharmaceutical reported a strong financial performance for 2024, with total revenue growth of 11% and adjusted EBITDA growth of 9%, while maintaining a net debt to adjusted EBITDA ratio of less than two times.

Strategic Initiatives: The company is focused on long-term shareholder value through disciplined capital deployment, including a $60 million share repurchase program and the completion of an acquisition.

Analyst Upgrade: Needham analyst Serge Belanger upgraded Collegium Pharmaceutical to a Buy rating with a price target of $46, citing higher-than-expected 2025 guidance and undervaluation compared to peers due to growth potential from its pain portfolio and new CNS products.

Market Performance: Despite the upgrade, COLL shares are trading lower at $33.00, reflecting ongoing concerns about generic competition and the company's historical discount valuation related to its opioid focus.

Record Price Increases: In the first two days of 2025, drugmakers raised prices on 583 products, marking the highest increase in list prices for the start of a new year since 2011, with only one significant price cut among drugs slated for Medicare negotiations.

Regulatory Pressure and Stock Outlook: Some companies reduced prices due to regulatory scrutiny, while analysts suggest that Eli Lilly (LLY) stock has significant upside potential, with an average target price indicating over 33% growth.

Approval of JORNAY PM™: Knight Therapeutics Inc. announced that Health Canada has approved JORNAY PM™, an evening-dosed extended-release methylphenidate for treating ADHD in children aged 6 to 12, which allows symptom control from morning until evening.

Market Impact and Future Plans: The launch of JORNAY PM™ is expected in the second half of 2025, contributing to Knight's growing ADHD portfolio, as the Canadian market for extended-release methylphenidate products was valued at $469 million in 2023, showing significant growth.

Earnings Conference Call Overview: Collegium Pharmaceutical held its Q3 2024 earnings conference call on November 7, 2024, featuring key executives including the Interim CEO and CFO, discussing company performance and future outlook.

Forward-Looking Statements Warning: The company cautioned participants about forward-looking statements related to risks in product commercialization, potential litigation, and integration challenges following the acquisition of Ironshore.

New Leadership Appointment: Vikram Karnani has been appointed as the new president and CEO of Collegium Pharmaceutical, effective November 12, while Michael Heffernan continues as chairman of the board.

Background Information: Prior to this role, Karnani was EVP and president of global commercial operations and medical affairs at Amgen.

Collegium Pharmaceutical Inc Performance: Shares of Collegium Pharmaceutical Inc (COLL) have entered oversold territory with an RSI reading of 29.98, indicating potential exhaustion of recent selling pressure and possible buying opportunities.

Stock Range Insights: COLL's 52-week range shows a low of $21.40 and a high of $42.2873, with the last trade recorded at $32.72.

Earnings Performance: Indivior PLC reported quarterly earnings of $0.54 per share, exceeding estimates and showing a year-over-year increase from $0.34. The company also achieved revenues of $307 million, surpassing expectations and reflecting growth from $271 million a year ago.

Stock Outlook: Despite the positive earnings report, Indivior's stock has underperformed this year, with a Zacks Rank of #5 (Strong Sell) indicating expected further underperformance in the near future. Investors are advised to monitor changes in earnings estimates and industry outlooks for potential impacts on stock performance.

Stock Performance Overview: COLL's stock has a 52-week low of $20.95 and a high of $42.2873, with the last trade recorded at $35.51.

Market Analysis Note: The article mentions other stocks that have recently fallen below their 200-day moving average.

Collegium Pharmaceutical Upgrade: Collegium Pharmaceutical (COLL) has received a Zacks Rank #2 (Buy) upgrade, indicating an upward trend in earnings estimates which could positively influence its stock price.

Earnings Estimate Revisions Impact: The Zacks rating system highlights the strong correlation between earnings estimate revisions and near-term stock movements, suggesting that the recent positive outlook for Collegium's earnings may lead to higher stock performance.

Analyst Rating Changes: Several Wall Street analysts adjusted their price targets and ratings for various companies, including C3.ai, Collegium Pharmaceutical, ChargePoint, S&P Global, Dollar Tree, Novartis, Core & Main, EVERTEC, Celanese, and StoneCo, reflecting a mix of upgrades and downgrades.

Market Reactions: Following these changes, stock prices reacted accordingly, with notable declines for Dollar Tree (22.2%) and Core & Main (15.8%), while S&P Global and Collegium Pharmaceutical saw slight gains.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate market insights.

Company Announcement: Collegium Pharmaceutical, Inc. will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024, at 12:30 p.m. ET, which will be webcast live.

Company Overview: Collegium is a diversified specialty pharmaceutical company based in Stoughton, Massachusetts, focused on improving the lives of individuals with serious medical conditions.

Collegium Pharmaceutical Q2 2024 Results: Collegium Pharmaceutical reported earnings per share of $1.62 and revenue of $145.28 million, surpassing analyst estimates for both metrics.

InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly provide key financial figures and comparisons to analyst expectations without human intervention.